Search results for "DELIVERY SYSTEM"

showing 10 items of 367 documents

Buccal Delivery of Methimazole as an Alternative Means for Improvement of Drug Bioavailability: Permeation Studies and Matrix System Design

2012

The aim of this study was to investigate the potential for systemic administration of Methimazole (MMI) through the buccal mucosa as an alternative route for drug delivery. Considering that the most important restriction in buccal drug delivery could be the low permeability of the mucosa, the ability of MMI to cross the mucosal barrier was assessed. Permeation of MMI through porcine buccal mucosa was investigated ex vivo using Franz type diffusion cells, buffer solution simulating saliva or natural human saliva as donor phase. The collected data suggested that buccal mucosa does not hinder MMI diffusion and the drug crosses the membrane (J(s) = 0.068 mg cm(-2) h(-1) and K(p) = 0.065 cm h(-1…

MaleDrugSwinemedia_common.quotation_subjectAcrylic ResinsBiological AvailabilityPharmacologyPermeabilityDosage formDiffusionExcipientsDrug Delivery SystemsAntithyroid Agentsstomatognathic systemDrug DiscoveryAnimalsHumansSalivamedia_commonPharmacologyMethimazoleChromatographyChemistryMouth MucosaAdministration BuccalBuccal administrationPermeationBioavailabilitySolubilityDrug deliverySystemic administrationEx vivoTabletsCurrent Pharmaceutical Design
researchProduct

Synaptosomes: new vesicles for neuronal mitochondrial transplantation

2021

Abstract Background Mitochondrial dysfunction is a critical factor in the onset and progression of neurodegenerative diseases. Recently, mitochondrial transplantation has been advised as an innovative and attractive strategy to transfer and replace damaged mitochondria. Here we propose, for the first time, to use rat brain extracted synaptosomes, a subcellular fraction of isolated synaptic terminal that contains mitochondria, as mitochondrial delivery systems. Results Synaptosome preparation was validated by the presence of Synaptophysin and PSD95. Synaptosomes were characterized in terms of dimension, zeta potential, polydispersity index and number of particles/ml. Nile Red or CTX-FITCH la…

MaleFIS1Mitochondrial DNAlcsh:Medical technologylcsh:BiotechnologyBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)BioengineeringMitochondrionDNA MitochondrialApplied Microbiology and BiotechnologyMembrane Potentials03 medical and health sciencesDrug Delivery Systems0302 clinical medicinelcsh:TP248.13-248.65medicineAnimalsHomeostasisProtein Interaction Domains and MotifsNeurodegenerationDelivery system030304 developmental biologyMitochondrial transplantationSynaptosome0303 health sciencesbiologyChemistryResearchCytochrome cNeurodegenerationSynaptosomes Mitochondria Neurodegeneration Delivery system Mitochondrial transplantationCytochromes cmedicine.diseaseRatsCell biologyMitochondriaTransplantationlcsh:R855-855.5Cytoplasmbiology.proteinMolecular Medicine030217 neurology & neurosurgerySubcellular FractionsSynaptosomes
researchProduct

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

2019

[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water at an acidic and a neutral pH show negligible dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is added because of hydrolysis of an azo bond in the capping ensemble. Additionally, olsalazine fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the colon. In vivo pharmacokinetic studies in rats show …

MaleHydrocortisoneTECNOLOGIA DE ALIMENTOSReducing agentPharmaceutical Science02 engineering and technologyMesoporous silica microparticles030226 pharmacology & pharmacyInflammatory bowel diseaseSodium dithionite03 medical and health scienceschemistry.chemical_compoundHydrolysisDrug Delivery Systems0302 clinical medicineQUIMICA ORGANICAIn vivoDrug DiscoveryQUIMICA ANALITICAmedicineRhodamine BAnimalsGated materialsRats WistarMesalamineOlsalazineRhodaminesColon targeted releaseQUIMICA INORGANICAMesoporous silicaColitisInflammatory Bowel DiseasesSilicon Dioxide021001 nanoscience & nanotechnologySmart drug delivery materialsRatschemistryDrug deliveryMolecular Medicine0210 nano-technologymedicine.drugNuclear chemistry
researchProduct

Polymeric Nanocarriers for Magnetic Targeted Drug Delivery: Preparation, Characterization, and in Vitro and in Vivo Evaluation

2013

In this paper the preparation of magnetic nano- carriers (MNCs), containing superparamagnetic domains, is reported, useful as potential magnetically targeted drug delivery systems. The preparation of MNCs was performed by using the PHEA-IB-p(BMA) graft copolymer as coating material through the homogenization−solvent evaporation method. Magnetic and nonmagnetic nanocarriers containing flutamide (FLU-MNCs) were prepared. The prepared nanocarriers have been exhaustively characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and magnetic measurements. Biological evaluation was performed by in vitro cytotoxicity and cell uptake tests and in vivo biodistribution …

MaleMaterials sciencePharmaceutical ScienceAntineoplastic AgentsNanotechnologyMagneticsDrug Delivery SystemsDynamic light scatteringIn vivoCell Line TumorDrug DiscoveryLNCaPAnimalsHumansDistribution (pharmacology)Tissue DistributionParticle SizeRats WistarMagnetite NanoparticlesDrug Carriersequipment and suppliesmagnetic nanocarrier magnetic targeting flutamide superparamagnetic nanoparticlesFlutamideIn vitroRatsTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsMolecular MedicineNanocarriersPeptideshuman activitiesSuperparamagnetismMolecular Pharmaceutics
researchProduct

Mitochondria as the target for mildronate's protective effects in azidothymidine (AZT)-induced toxicity of isolated rat liver mitochondria

2008

Previously mildronate, an aza-butyrobetaine derivative, was shown to be a cytoprotective drug, through its mechanism of action of inhibition of carnitine palmitoyltransferase-1, thus protecting mitochondria from long-chain fatty acid accumulation and subsequent damage. Recently in an azidothymidine (AZT)-induced cardiotoxicity model in vivo (in mice), we have found mildronate's ability of protecting heart tissue from nuclear factor kappaB abnormal expression. Preliminary data also demonstrate cerebro- and hepatoprotecting properties of mildronate in AZT-toxicity models. We suggest that mildronate may target its action predominantly to mitochondria. The present study in isolated rat liver mi…

MaleMitochondrial DiseasesBioenergeticsAntimetabolitesCell RespirationClinical BiochemistryMitochondria LiverIn Vitro TechniquesMitochondrionPharmacologyBiologymedicine.disease_causeBiochemistryPermeabilityRespiratory electron transport chainDrug Delivery SystemsmedicineAnimalsCarnitineRats WistarCardiotoxicityCell BiologyGeneral MedicineRatsDisease Models AnimalMechanism of actionBiochemistryToxicitymedicine.symptomEnergy MetabolismZidovudineOxidative stressMethylhydrazinesmedicine.drug
researchProduct

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study

2017

Background The vast majority of prostate cancer presents clinically localized to the prostate without evidence of metastasis. Currently, there are several modalities available to treat this particular disease. Despite radical prostatectomy demonstrating a modest prostate cancer specific mortality benefit in the PIVOT trial, several novel modalities have emerged to treat localized prostate cancer in patients that are either not eligible for surgery or that prefer an alternative approach. Methods Athymic nude mice were subcutaneously inoculated with prostate cancer cells. The mice were divided into four cohorts, one cohort untreated, two cohorts received docetaxel (10 mg/kg) either subcutaneo…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentMice NudeAntineoplastic AgentsDocetaxel02 engineering and technologyMetastasisMice03 medical and health sciencesProstate cancerDrug Delivery Systems0302 clinical medicineProstateIn vivoInternal medicinemedicineAnimalsMinimally Invasive Surgical ProceduresProstatectomybusiness.industryProstatectomyProstatic NeoplasmsProstate-Specific Antigen021001 nanoscience & nanotechnologymedicine.diseaseTumor BurdenSurgeryTreatment Outcomemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisCohortMagnetsImmunohistochemistryTaxoidsDrug Monitoring0210 nano-technologybusinessmedicine.drugThe Prostate
researchProduct

INULIN BASED HYDROGEL FOR ORAL DELIVERY OF FLUTAMIDE: PREPARATION, CHARACTERIZATION AND IN VIVO RELEASE STUDIES

2012

The ability of a hydrogel obtained by crosslinking INUDV and PEGBa to facilitate sustained release of flutamide is examined. The hydrogel is prepared in pH = 7.4 PBS and no toxic solvents or catalysts are used. It is recovered in microparticulate form and its size distribution is determined. Mucoadhesive properties are evaluated in vitro by reproducing gastrointestinal conditions. Flutamide is loaded into the hydrogel using a post-fabrication encapsulation procedure that allows a drug loading comparable to that of market tablets. Drug-loaded microparticles are orally administered to cross-bred dogs and the in vivo study demonstrates their ability to prolong the half-life of the principal ac…

MalePolymers and PlasticsInulinAdministration OralBiological AvailabilityBioengineeringPharmacologyFlutamideBiomaterialschemistry.chemical_compoundDogsDrug Delivery SystemsIn vivoMaterials ChemistryDistribution (pharmacology)AnimalsHypoglycemic AgentsInsulinActive metabolitetechnology industry and agricultureAndrogen AntagonistsHydrogelsIn vitroFlutamideBioavailabilitychemistrySelf-healing hydrogelsBiotechnologyHalf-Life
researchProduct

Polyhydroxyethylaspartamide-based micelles for ocular drug delivery

2009

In this paper three copolymers of polyhydroxyethylaspartamide (PHEA), bearing in the side chains polyethylene glycol (PEG) and/or hexadecylamine (C(16)) (PHEA-PEG, PHEA-PEG-C(16) and PHEA-C(16) respectively) have been studied as potential colloidal drug carriers for ocular drug delivery. The physical characterization of all three PHEA derivatives, using the Langmuir trough (LT) and micellar affinity capillary electrophoresis (MACE) techniques allowed to assume that whereas alone PHEA backbone is an inert polymer with respect to the interactions with lipid membranes and drug complexation, when PHEA chains are grafted with long alkyl chains like C(16) or in combination C(16) chains and hydrop…

MalePolymersAdministration TopicalBiological AvailabilityPharmaceutical SciencePolyethylene glycolMicelleDexamethasonePermeabilityPolyethylene Glycolschemistry.chemical_compoundocular drug delivery systemIn vivoPEG ratioAnimalsColloidsNetilmicinAminesLipid bilayerMicellesDrug CarriersChromatographyChemistryEpithelium Cornealtechnology industry and agricultureHydrocarbonsBioavailabilityDrug deliverypolymeric micelles amphiphilic copolymersRabbitsPeptidesDrug carrierConjunctiva
researchProduct

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases

2019

Abstract Hypoxic pulmonary vasoconstriction (HPV) is a well-characterized vascular response to low oxygen pressures and is involved in life-threatening conditions such as high-altitude pulmonary edema (HAPE) and pulmonary arterial hypertension (PAH). While the efficacy of oral therapies can be affected by drug metabolism, or dose-limiting systemic toxicity, inhaled treatment via pressured metered dose inhalers (pMDI) may be an effective, nontoxic, practical alternative. We hypothesized that a stable water-in-perfluorooctyl bromide (PFOB) emulsion that provides solubility in common pMDI propellants, engineered for intrapulmonary delivery of pulmonary vasodilators, reverses HPV during acute h…

MalePulmonary CirculationDrug Evaluation PreclinicalPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacyRats Sprague-DawleyDrug Delivery Systems0302 clinical medicineHypoxic pulmonary vasoconstrictionHigh-altitude pulmonary edemapulmonary hypertensionMedicineFluorocarbonsPhenylpropionatesmedicine.diagnostic_testGeneral Medicine021001 nanoscience & nanotechnologyPulmonary edema3. Good healthPyridazinesTreatment Outcomemedicine.anatomical_structureEmulsions0210 nano-technologyendothelinResearch Articlemedicine.drugpulmonary pressuresAmbrisentanambrisentanHypertension PulmonaryPulmonary Edema03 medical and health sciencesmedicine.arteryAnimalsAntihypertensive AgentsLungsodium nitriteperfluorocarbonbusiness.industrylcsh:RM1-950Watermedicine.diseasePulmonary hypertensionRatsBronchoalveolar lavagelcsh:Therapeutics. PharmacologyPulmonary arteryhigh altitude pulmonary edemabusinessDrug Delivery
researchProduct

Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Blood–Brain Barrier

2013

The relevant parameters for predicting rate and extent of access across the blood-brain barrier (BBB) are fu,plasma (unbound fraction in plasma), Vu,brain (distribution volume in brain) and Kp,uu,brain (ratio of free concentrations in plasma and brain). Their estimation still requires animal studies and in vitro low throughput experiments which make difficult the screening of new CNS candidates. The aim of the present work was to develop a new whole in vitro high throughput method to predict drug rate and extent of access across the BBB. The system permits estimation of fu,plasma, Vu,brain and Kp,uu,brain in a single experimental system, using in vitro cell monolayers in different condition…

MaleSwineChemistryHigh-throughput screeningDrug delivery to the brainAlbuminBrainPharmaceutical ScienceModels TheoreticalPharmacologyBlood–brain barrierIn vitroCell LineDogsDrug Delivery Systemsmedicine.anatomical_structureBlood-Brain BarrierIn vivoCell cultureDrug DiscoverymedicineAnimalsMolecular MedicineAnimal studiesMolecular Pharmaceutics
researchProduct